These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
246 related items for PubMed ID: 22964245
1. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Moss JA, Malone AM, Smith TJ, Butkyavichene I, Cortez C, Gilman J, Kennedy S, Kopin E, Nguyen C, Sinha P, Hendry RM, Guenthner P, Holder A, Martin A, McNicholl J, Mitchell J, Pau CP, Srinivasan P, Smith JM, Baum MM. Antimicrob Agents Chemother; 2012 Nov; 56(11):5952-60. PubMed ID: 22964245 [Abstract] [Full Text] [Related]
2. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. Moss JA, Srinivasan P, Smith TJ, Butkyavichene I, Lopez G, Brooks AA, Martin A, Dinh CT, Smith JM, Baum MM. Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594 [Abstract] [Full Text] [Related]
3. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Moss JA, Malone AM, Smith TJ, Kennedy S, Kopin E, Nguyen C, Gilman J, Butkyavichene I, Vincent KL, Motamedi M, Friend DR, Clark MR, Baum MM. Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689 [Abstract] [Full Text] [Related]
4. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. Thurman AR, Schwartz JL, Ravel J, Gajer P, Marzinke MA, Yousefieh N, Anderson SM, Doncel GF. PLoS One; 2019 Feb; 14(5):e0217229. PubMed ID: 31107913 [Abstract] [Full Text] [Related]
5. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Moss JA, Butkyavichene I, Churchman SA, Gunawardana M, Fanter R, Miller CS, Yang F, Easley JT, Marzinke MA, Hendrix CW, Smith TJ, Baum MM. Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321 [Abstract] [Full Text] [Related]
6. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Johnson TJ, Clark MR, Albright TH, Nebeker JS, Tuitupou AL, Clark JT, Fabian J, McCabe RT, Chandra N, Doncel GF, Friend DR, Kiser PF. Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751 [Abstract] [Full Text] [Related]
7. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM. PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679 [Abstract] [Full Text] [Related]
8. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques. Dobard CW, Sharma S, Cong ME, West R, Makarova N, Holder A, Pau CP, Hanson DL, Novembre FJ, Garcia-Lerma JG, Heneine W. Retrovirology; 2015 Aug 08; 12():69. PubMed ID: 26253002 [Abstract] [Full Text] [Related]
9. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. Thurman AR, Schwartz JL, Brache V, Clark MR, McCormick T, Chandra N, Marzinke MA, Stanczyk FZ, Dezzutti CS, Hillier SL, Herold BC, Fichorova R, Asin SN, Rollenhagen C, Weiner D, Kiser P, Doncel GF. PLoS One; 2018 Aug 08; 13(6):e0199778. PubMed ID: 29953547 [Abstract] [Full Text] [Related]
11. Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Pereira LE, Clark MR, Friend DR, Garber DA, McNicholl JM, Hendry RM, Doncel GF, Smith JM. Antimicrob Agents Chemother; 2014 May 08; 58(5):2665-74. PubMed ID: 24566178 [Abstract] [Full Text] [Related]
18. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W. J Virol; 2009 Oct 08; 83(20):10358-65. PubMed ID: 19656878 [Abstract] [Full Text] [Related]
19. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya. Mugo NR, Mudhune V, Heffron R, Thomas KK, McLellan-Lemal E, Njoroge B, Peacock S, O'Connor SM, Nyagol B, Ouma E, Ridzon R, Wiener J, Isoherranen N, Erikson DW, Ouattara LA, Yousefieh N, Jacot TA, Haaland RE, Morrison SA, Haugen HS, Thurman AR, Allen SA, Baeten JM, Samandari T, Doncel GF. Front Reprod Health; 2023 Oct 08; 5():1118030. PubMed ID: 37383290 [Abstract] [Full Text] [Related]
20. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. Smith JM, Moss JA, Srinivasan P, Butkyavichene I, Gunawardana M, Fanter R, Miller CS, Sanchez D, Yang F, Ellis S, Zhang J, Marzinke MA, Hendrix CW, Kapoor A, Baum MM. PLoS One; 2017 Oct 08; 12(10):e0185946. PubMed ID: 28982161 [Abstract] [Full Text] [Related] Page: [Next] [New Search]